AU2432102A - Lactam compound - Google Patents

Lactam compound

Info

Publication number
AU2432102A
AU2432102A AU2432102A AU2432102A AU2432102A AU 2432102 A AU2432102 A AU 2432102A AU 2432102 A AU2432102 A AU 2432102A AU 2432102 A AU2432102 A AU 2432102A AU 2432102 A AU2432102 A AU 2432102A
Authority
AU
Australia
Prior art keywords
lactam compound
lactam
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2432102A
Other languages
English (en)
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2432102A publication Critical patent/AU2432102A/xx
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
AU2432102A 2000-11-17 2001-11-02 Lactam compound Pending AU2432102A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (1)

Publication Number Publication Date
AU2432102A true AU2432102A (en) 2002-05-27

Family

ID=22944436

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2432102A Pending AU2432102A (en) 2000-11-17 2001-11-02 Lactam compound
AU2002224321A Ceased AU2002224321B2 (en) 2000-11-17 2001-11-02 Lactam compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002224321A Ceased AU2002224321B2 (en) 2000-11-17 2001-11-02 Lactam compound

Country Status (33)

Country Link
US (1) US20040248878A1 (cg-RX-API-DMAC7.html)
EP (1) EP1353910B1 (cg-RX-API-DMAC7.html)
JP (1) JP4116431B2 (cg-RX-API-DMAC7.html)
KR (1) KR20030045194A (cg-RX-API-DMAC7.html)
CN (2) CN101624372A (cg-RX-API-DMAC7.html)
AR (1) AR031356A1 (cg-RX-API-DMAC7.html)
AT (1) ATE362919T1 (cg-RX-API-DMAC7.html)
AU (2) AU2432102A (cg-RX-API-DMAC7.html)
BR (1) BR0115424A (cg-RX-API-DMAC7.html)
CA (1) CA2425497C (cg-RX-API-DMAC7.html)
CY (1) CY1106682T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031340A3 (cg-RX-API-DMAC7.html)
DE (1) DE60128587T2 (cg-RX-API-DMAC7.html)
DK (1) DK1353910T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3454A1 (cg-RX-API-DMAC7.html)
EA (1) EA006919B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034598A (cg-RX-API-DMAC7.html)
ES (1) ES2286162T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030385A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301862A3 (cg-RX-API-DMAC7.html)
IL (1) IL155275A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03004250A (cg-RX-API-DMAC7.html)
MY (1) MY141607A (cg-RX-API-DMAC7.html)
NO (1) NO325217B1 (cg-RX-API-DMAC7.html)
PE (1) PE20020798A1 (cg-RX-API-DMAC7.html)
PL (1) PL211018B1 (cg-RX-API-DMAC7.html)
PT (1) PT1353910E (cg-RX-API-DMAC7.html)
SK (1) SK287794B6 (cg-RX-API-DMAC7.html)
SV (1) SV2003000741A (cg-RX-API-DMAC7.html)
TW (1) TWI235151B (cg-RX-API-DMAC7.html)
UA (1) UA77165C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002040451A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200303411B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
TWI323256B (en) 2002-12-20 2010-04-11 Glaxo Group Ltd Novel benzazepine derivatives and pharmaceutical compositions comprising said compounds
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RU2404968C2 (ru) 2005-04-08 2010-11-27 Дайити Санкио Компани, Лимитед Пиридилдиметилсульфоновое производное
US8258302B2 (en) 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP2987496B1 (en) 2013-04-19 2018-08-08 National University Corporation Okayama University Treatment agent for cognitive disorders, induced by amyloid -protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
KR20230005163A (ko) 2020-03-26 2023-01-09 씨젠 인크. 다발성 골수종 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158355A0 (en) * 1996-12-23 2004-05-12 Elan Pharm Inc CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2002518481A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチドの放出および/またはその合成を阻害するための化合物
CA2390376A1 (en) * 1999-11-09 2001-05-17 William Leonard Scott .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis

Also Published As

Publication number Publication date
DZ3454A1 (fr) 2002-05-23
AR031356A1 (es) 2003-09-17
AU2002224321B2 (en) 2006-10-19
HUP0301862A3 (en) 2007-09-28
CY1106682T1 (el) 2012-05-23
JP4116431B2 (ja) 2008-07-09
IL155275A0 (en) 2003-11-23
NO20032215L (no) 2003-07-16
PL360991A1 (en) 2004-09-20
ZA200303411B (en) 2004-08-02
CA2425497A1 (en) 2002-05-23
NO325217B1 (no) 2008-02-25
MXPA03004250A (es) 2003-09-22
NO20032215D0 (no) 2003-05-15
EP1353910B1 (en) 2007-05-23
JP2004521084A (ja) 2004-07-15
CN1575282A (zh) 2005-02-02
SK5432003A3 (en) 2004-09-08
DK1353910T3 (da) 2007-09-10
PL211018B1 (pl) 2012-03-30
DE60128587T2 (de) 2008-01-31
MY141607A (en) 2010-05-31
HUP0301862A2 (hu) 2003-09-29
PE20020798A1 (es) 2002-09-06
WO2002040451A3 (en) 2003-08-28
SV2003000741A (es) 2003-01-13
TWI235151B (en) 2005-07-01
EA200300579A1 (ru) 2003-12-25
WO2002040451A2 (en) 2002-05-23
BR0115424A (pt) 2003-10-21
EP1353910A2 (en) 2003-10-22
CZ20031340A3 (cs) 2004-06-16
HRP20030385A2 (en) 2003-08-31
EA006919B1 (ru) 2006-04-28
PT1353910E (pt) 2007-08-20
CA2425497C (en) 2010-08-17
ATE362919T1 (de) 2007-06-15
US20040248878A1 (en) 2004-12-09
SK287794B6 (sk) 2011-10-04
KR20030045194A (ko) 2003-06-09
DE60128587D1 (de) 2007-07-05
UA77165C2 (en) 2006-11-15
ES2286162T3 (es) 2007-12-01
CN101624372A (zh) 2010-01-13
CN100516047C (zh) 2009-07-22
ECSP034598A (es) 2003-06-25

Similar Documents

Publication Publication Date Title
AU4319202A (en) Lactam compound
EP1349851A4 (en) COMPOUNDS
AU2432102A (en) Lactam compound
AU2405002A (en) Dehalogeno compounds
IL153180A0 (en) Polyamides
GB0113781D0 (en) Compound
PH12001001591B1 (en) Polyamides
HK1061390A (en) Lactam compound
GB0027046D0 (en) Compound
GB0019377D0 (en) Compound
GB0018040D0 (en) Compound
GB0004317D0 (en) Compound
GB0018529D0 (en) Compound
GB0031061D0 (en) Novel compound
HU0402189D0 (en) Intermediate compounds
SI1297052T1 (sl) Poliamidi
GB0003631D0 (en) Compounds
GB0003608D0 (en) Compounds
GB0005574D0 (en) Compounds
GB0003600D0 (en) Compounds
GB0003599D0 (en) Compounds
GB0003609D0 (en) Compounds
GB0005387D0 (en) Compounds
GB0005370D0 (en) Compounds
GB0004053D0 (en) Compounds